CANCER MECHANISMS RESEARCH PROGRAM

癌症机制研究计划

• 批准号: 7944607
• 负责人: Charles M Brenner
• 金额: $ 2.7万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-21 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944607
• 关键词: Apoptosis Regulator; Basic Science; Biological Factors; Blood; Breast; Cancer Center Support Grant; Cancer Research Project; Cell Cycle; Cessation of life; Chimeric Proteins; Classification; Clinical; Collaborations; Community Clinical Oncology Program; Complex; Development; Drug Delivery Systems; Fostering; Funding; Genotype; Goals; Hematologic Neoplasms; Hereditary Disease; Incidence; Intestines; Lead; Leadership; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Medical center; Mission; Molecular; Neoplasm Metastasis; Nerve Degeneration; Pain; Paper; Pathway interactions; Population; Prevention; Publishing; Research; Research Personnel; Research Project Grants; Resource Sharing; Role; Scientist; Stem cells; Suppressor Genes; Translating; Translational Research; Tumor Suppressor Genes; angiogenesis; cancer diagnosis; cancer stem cell; cancer therapy; carcinogenesis; carcinogenesis inhibitor; chemotherapy; college; cost; disease classification; gene discovery; interdisciplinary collaboration; interest; medical schools; meetings; member; mouse model; neuro-oncology; programs; small molecule

The mission of the Cancer Mechanisms Program (CM) is to foster interdisciplinary collaborations and accelerate progress along the translational continuum between gene discovery and genotype-informed molecular treatments. CM organizes cancer-focused basic science on the Dartmouth Medical School, Dartmouth College, and Dartmouth-Hitchcock Medical Center campuses. CM investigators have common interests in dissecting the normal functions of oncogenes and tumor suppressor genes; regulators of cell cycle and apoptosis; regulators of angiogenesis and metastasis; and stem cells and blood formation. The CM Program adds value by channeling efforts toward three translational aims: molecular disease classification; drug target and lead compound identification; and understanding the complex interactions of small molecules and genotypes in carcinogenesis and treatment. By promoting collaborations among basic and clinical scientists from 10 departments, the 25-member Program has created advances that no single investigator could have made. CM investigators conduct research projects with a current annual total cost funding of $12.9 million ($2.9 million from NCI). Program members published more than 150 papers during the renewal period, of which 15% derived from intra-programmatic and 44% from inter-programmatic collaborations. CM has also assumed a leadership role in establishing and participating in comprehensive breast, lung, gastro-intestinal and neuro-oncology programs, thus uniting basic scientists with population scientists and clinicians to promote bidirectional translational research. CM scientists also organized regional and national meetings in hematological malignancies, lung cancer, and stem cells, out of which productive collaborations were formed. Going forward, CM will exploit advances such as a new mouse model for lung cancer to evaluate inhibitors of carcinogenesis, new targeted lead compounds against leukemogenic fusion proteins, and a newly discovered natural product that protects against chemotherapy-induced neurodegeneration, thereby translating CM discoveries to reduce cancer incidence, cancer death, and the pain and suffering associated with cancer treatment.

癌症机制计划 (CM) 的使命是促进跨学科合作和 加速基因发现和基因型信息之间的转化连续体的进展 分子治疗。 CM 在达特茅斯医学院组织以癌症为重点的基础科学， 达特茅斯学院和达特茅斯-希区柯克医学中心校园。 CM 调查人员有共同点 对剖析癌基因和抑癌基因的正常功能感兴趣；细胞调节因子 周期和细胞凋亡；血管生成和转移的调节因子；以及干细胞和血液形成。这 CM 计划通过将努力引导到三个转化目标来增加价值：分子疾病 分类;药物靶点和先导化合物鉴定；并理解复杂的相互作用 致癌和治疗中的小分子和基因型。通过促进基础设施之间的合作 以及来自 10 个部门的临床科学家，这个由 25 名成员组成的计划取得了前所未有的进步 调查员本来可以做的。 CM 研究人员开展当前年度总成本的研究项目 资金 1290 万美元（290 万美元来自 NCI）。项目成员发表论文150余篇 续订期，其中 15% 来自程序内，44% 来自程序间 合作。 CM 还在建立和参与综合乳、肺、 胃肠道和神经肿瘤学项目，从而将基础科学家与人口科学家联合起来 临床医生促进双向转化研究。 CM 科学家还组织了区域和国家 血液恶性肿瘤、肺癌和干细胞会议，其中富有成效的合作 成立了。展望未来，CM 将利用新的肺癌小鼠模型等先进技术来 评估致癌抑制剂、抗白血病融合蛋白的新靶向先导化合物、 以及一种新发现的天然产物，可以防止化疗引起的神经变性， 从而将 CM 发现转化为减少癌症发病率、癌症死亡以及疼痛和折磨 与癌症治疗有关。